Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03321019 · ClinicalTrials.gov registry record
Airway Protective Mechanisms in PD (R01)
A clinical trial, sponsored by University of Florida.
- Completed
- Registry status
- 119
- Enrollment target
NCT03321019: Completed study, sponsored by University of Florida.
NCT03321019 is a clinical trial that has completed, run by University of Florida. The registered enrollment target is 119 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03321019 has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- 119 participants
- Enrollment target
Study Summary
This study will collect data on various aspects of airway sensation and function, and determine how it relates to the development of swallowing and cough dysfunction in Parkinson's disease. Participants will be followed over a 3-year period, with once-per-year visits to collect the data.
Primary Outcome
Slope of perception of resistive load and load resistance: Magnitude estimation of respiratory load (6 - no difficulty inhaling - 20 maximum difficulty inhaling) is plotted on the y-axis and respiratory load (0, 5, 10, 25 \& 40 cm H2O loads) is plotted on the x-axis. The slope of the resulting regression line is the measure.
Interventions
- DRUG Capsaicin
- DEVICE Resistive respiratory loads
- OTHER Event-related evoked potential using electroencephalography (EEG).
- PROCEDURE Fluoroscopic swallow evaluation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2017-12-12 |
| Est. Completion | 2023-09-29 |
What the finished NCT03321019 record still lists
NCT03321019 is an observational study that tracks outcomes without assigning an intervention. The registered 119 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 4 interventions - of which Capsaicin is the first listed.
NCT03321019 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03321019 about?
NCT03321019 is a clinical study titled "Airway Protective Mechanisms in PD (R01)". This study will collect data on various aspects of airway sensation and function, and determine how it relates to the development of swallowing and cough dysfunction in Parkinson's disease. Participants will be followed over a 3-year period, with once-per-year visits to collect the data.
What is the current status of trial NCT03321019?
This trial is currently completed. The enrollment target is 119 participants. The study started on 2017-12-12. Estimated completion is 2023-09-29.
What interventions are being tested in trial NCT03321019?
The interventions under investigation include: Capsaicin (DRUG), Resistive respiratory loads (DEVICE), Event-related evoked potential using electroencephalography (EEG). (OTHER), Fluoroscopic swallow evaluation (PROCEDURE).
Who is sponsoring clinical trial NCT03321019?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04870762 · 119 participants · Phase 2
Customized 3D Printed Oral Stents During Head and Neck Radiotherapy
- NCT05559853 · 119 participants
Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
- NCT06564389 · 119 participants · Phase 1
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
- NCT06742801 · 119 participants · NA
Onyx™ Liquid Embolic IDE Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI